0001171843-26-002722
SEC filingEvaxion Biotech A/S promotes Birgitte Rønø to dual role of Chief Scientific Officer and Chief Operating Officer to enhance external engagement and strategy execution.
The promotion of Birgitte Rønø to the combined CSO and COO role is designed to streamline Evaxion’s operations amid its focus on advancing the AI-Immunology™ platform for vaccine development. This change recognizes her extensive internal contributions and scientific leadership, positioning the management team to better engage partners and investors on the platform’s capabilities in immune target discovery and clinical validation. With a lean executive structure including CEO Helen Tayton-Martin, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson, Evaxion aims to efficiently execute its strategy in cancer and infectious disease vaccines.